IDEAYA Biosciences, Inc. – NASDAQ:IDYA

Add to watchlist

$23.58

-1.58

-6.28%

Market closed

Open in about 15 hours

-37.10%

month

-37.10%

quarter

-28.81%

year

Market Cap	2.18B
Enterprise value	499.32M

P/E	-8.79
EV/Sales	9.80
EV/EBITDA	-9.11
Price/Sales	11.08
Price/Book	1.61
PEG ratio	12.39
EPS	-2.01

Revenue	N/A
EBITDA	-158.14M
Income	-128.89M
Revenue Q/Q	-100%
Revenue Y/Y	-67.32%

Profit margin	-119.27%
Oper. margin	-122.72%
Gross margin	0%
EBIT margin	-122.72%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

IDEAYA Biosciences Stock Forecast

M Q Y

Last Year

$54.11

Potential upside: 129.47%

Analysts Price target
Financials & Ratios estimates

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Profit margin
Jun 2023	3.54M	-27.92M	-787.98%
Sep 2023	8.03M	-27.44M	-341.38%
Dec 2023	3.92M	-33.95M	-865.54%
Mar 2024	0	-39.57M

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Debt to assets
Jun 2023	527557000	527.55M	100%
Sep 2023	532942000	24.89M	4.67%
Dec 2023	649316000	28.22M	4.35%
Mar 2024	961527000	26.21M	2.73%

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Cash Flow
Jun 2023	-33.46M	-121.38M	191.06M
Sep 2023	-30.17M	51.34M	27.83M
Dec 2023	-23.74M	-111.94M	140.89M
Mar 2024	-43.81M	-353.97M	349.11M

IDEAYA Biosciences alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Employee count
Sep 2023	116
Oct 2023	116
Nov 2023	116
Dec 2023	122
Jan 2024	122
Feb 2024	122
Mar 2024	124
Apr 2024	124
May 2024	124
Jun 2024	124
Jul 2024	124

IDEAYA Biosciences
Hedge Funds Holdings Q1 2023

35.22% -64.78%

of IDYA is owned by hedge funds

72 -46

hedge funds hold IDYA stock

14.59M -31.47M

shares is hold by hedge funds

IDYA hedge funds holdings changes

IDEAYA Biosciences
Insider Trading

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Insider trades (number of shares)
Period	Buy	Sel
Jul 2023	0	9485
Aug 2023	0	17500
Sep 2023	0	6837
Nov 2023	0	5163
Dec 2023	0	87000
Jan 2024	0	79000
Feb 2024	0	102000
May 2024	0	203500

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	27 Jun 2024	THRONE JASON officer: Chief Le..	Common Stock	47,060	$7.01	$329,891
Option	27 Jun 2024	THRONE JASON officer: Chief Le..	Stock Option (Right to Buy)	6,424	$13.34	$85,696
Option	27 Jun 2024	THRONE JASON officer: Chief Le..	Common Stock	6,424	$13.34	$85,696
Option	27 Jun 2024	THRONE JASON officer: Chief Le..	Stock Option (Right to Buy)	47,060	$7.01	$329,891
Option	29 May 2024	WHITE MICHAEL ANTHONY officer: Chief Scientific Officer officer: Chief Scientific Officer	Stock Option (right to buy)	28,500	$12.86	$366,510
Option	29 May 2024	WHITE MICHAEL ANTHONY officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	28,500	$12.86	$366,510
Sale	29 May 2024	WHITE MICHAEL ANTHONY officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	27,649	$36.23	$1,001,585
Sale	29 May 2024	WHITE MICHAEL ANTHONY officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	851	$36.78	$31,296
Option	16 May 2024	HATA YUJIRO S director, officer..	Common Stock	34,433	$4.31	$148,406
Sale	16 May 2024	HATA YUJIRO S director, officer..	Common Stock	30,084	$41.73	$1,255,496

IDYA insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application DIHYDROTHIENO[3,2-b]PYRIDINE COMPOUNDS Filling date: 25 Sep 2018 Issue date: 21 Jul 2022	25 Sep 2018	21 Jul 2022
Application	Application 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Filling date: 9 Dec 2019 Issue date: 7 Apr 2022	9 Dec 2019	7 Apr 2022
Application	Application ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Filling date: 29 Jan 2020 Issue date: 31 Mar 2022	29 Jan 2020	31 Mar 2022
Application	Application HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Filling date: 30 Jan 2020 Issue date: 16 Dec 2021	30 Jan 2020	16 Dec 2021
Application	Application METHODS OF INHIBITING PROLIFERATIVE CELLS Filling date: 17 Jun 2019 Issue date: 2 Dec 2021	17 Jun 2019	2 Dec 2021
Grant	Grant Utility: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors Filling date: 12 Feb 2021 Issue date: 28 Sep 2021	12 Feb 2021	28 Sep 2021
Application	Application METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING LACTAM COMPOUNDS Filling date: 5 Jun 2019 Issue date: 19 Aug 2021	5 Jun 2019	19 Aug 2021
Grant	Grant Utility: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors Filling date: 12 Feb 2021 Issue date: 10 Aug 2021	12 Feb 2021	10 Aug 2021
Grant	Grant Utility: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors Filling date: 12 Feb 2021 Issue date: 29 Jun 2021	12 Feb 2021	29 Jun 2021
Application	Application AMIDO COMPOUNDS AS AhR MODULATORS Filling date: 18 Jul 2018 Issue date: 22 Apr 2021	18 Jul 2018	22 Apr 2021

IDEAYA Biosciences
Earnings Call Transcripts

Quarter	Transcript
Q4 2021 15 Mar 2022	Q4 2021 Earnings Call Transcript

IDYA earnings call transcripts

IDEAYA Biosciences
Executives

Insider	Age	Compensation
Mr. Yujiro S. Hata (1974) Co-Founder, Chief Executive Officer, Pres & Director	51	$711,330
Mr. Paul A. Stone (1964) Senior Vice President, Chief Financial Officer & Principal Accounting Officer	61	$508,440
Mr. Jason S. Throne J.D., Esq. (1972) Senior Vice President, Gen. Counsel & Company Sec.	53	$425,560

IDEAYA Biosciences
Latest News

Sunday, 29 December 2024
06:00	IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors	prnewswire.com
Friday, 27 December 2024
06:00	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Tuesday, 17 December 2024
06:00	IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma	prnewswire.com
Monday, 16 December 2024
06:00	IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers	prnewswire.com
Wednesday, 11 December 2024
06:00	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024	prnewswire.com
Tuesday, 10 December 2024
06:00	IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer	prnewswire.com
Monday, 9 December 2024
06:00	IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor	prnewswire.com
Friday, 6 December 2024
06:00	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Wednesday, 4 December 2024
14:00	Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash	seekingalpha.com
Monday, 2 December 2024
06:00	IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events	prnewswire.com
Friday, 29 November 2024
06:00	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Monday, 18 November 2024
06:00	IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer	prnewswire.com
Tuesday, 12 November 2024
06:00	IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day	prnewswire.com
Monday, 11 November 2024
06:00	IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen	prnewswire.com
06:00	Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise	businesswire.com
06:00	Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise	businesswire.com
Thursday, 7 November 2024
11:00	Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know	zacks.com
Monday, 4 November 2024
06:00	IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update	prnewswire.com
Friday, 1 November 2024
06:00	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Tuesday, 29 October 2024
11:06	Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline	zacks.com
Monday, 28 October 2024
06:00	IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors	prnewswire.com
Friday, 25 October 2024
06:00	IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024	prnewswire.com
Friday, 4 October 2024
06:00	IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium	prnewswire.com
Friday, 27 September 2024
06:00	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Monday, 23 September 2024
10:07	Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate	benzinga.com
06:00	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma	prnewswire.com
Sunday, 22 September 2024
09:00	IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024	prnewswire.com
Friday, 20 September 2024
12:45	Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success	seekingalpha.com
Friday, 30 August 2024
06:00	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	prnewswire.com
Monday, 26 August 2024
06:00	IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	prnewswire.com

Ideas & Opinions

Seeking Alpha 5 Aug 2025

Ideaya Biosciences: Moving Into ADCs For Solid Tumors
Seeking Alpha 12 Jun 2025

Delcath Systems: Growing Fast, But Business Model Is Fragile
Seeking Alpha 14 May 2025

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
Seeking Alpha 16 Apr 2025

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later
Seeking Alpha 17 Nov 2023

Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Seeking Alpha 13 Sep 2023

IDEAYA's Triple Threat: Melanoma, Money, And Momentum
Seeking Alpha 11 Aug 2023

Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead
Seeking Alpha 24 Mar 2023

Ideaya Biosciences Has A Strong Pipeline And Looks Investible
Seeking Alpha 6 Oct 2022

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Seeking Alpha 7 Sep 2022

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

Frequently Asked Questions (FAQ)

What's the price of IDEAYA Biosciences stock today?

One share of IDEAYA Biosciences stock can currently be purchased for approximately $23.58.
When is IDEAYA Biosciences's next earnings date?

Unfortunately, IDEAYA Biosciences's (IDYA) next earnings date is currently unknown.
Does IDEAYA Biosciences pay dividends?

No, IDEAYA Biosciences does not pay dividends.
How much money does IDEAYA Biosciences make?

IDEAYA Biosciences has a market capitalization of 2.18B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 54.08% to 23.39M US dollars.
What is IDEAYA Biosciences's stock symbol?

IDEAYA Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "IDYA".
What is IDEAYA Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of IDEAYA Biosciences?

Shares of IDEAYA Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are IDEAYA Biosciences's key executives?
IDEAYA Biosciences's management team includes the following people:
- Mr. Yujiro S. Hata Co-Founder, Chief Executive Officer, Pres & Director(age: 51, pay: $711,330)
- Mr. Paul A. Stone Senior Vice President, Chief Financial Officer & Principal Accounting Officer(age: 61, pay: $508,440)
- Mr. Jason S. Throne J.D., Esq. Senior Vice President, Gen. Counsel & Company Sec.(age: 53, pay: $425,560)
Is IDEAYA Biosciences founder-led company?

Yes, IDEAYA Biosciences is a company led by its founder Mr. Yujiro S. Hata.
How many employees does IDEAYA Biosciences have?

As Jul 2024, IDEAYA Biosciences employs 124 workers.
When IDEAYA Biosciences went public?

IDEAYA Biosciences, Inc. is publicly traded company for more then 6 years since IPO on 23 May 2019.
What is IDEAYA Biosciences's official website?

The official website for IDEAYA Biosciences is ideayabio.com.
Where are IDEAYA Biosciences's headquarters?

IDEAYA Biosciences is headquartered at 7000 Shoreline Court, South San Francisco, CA.
How can i contact IDEAYA Biosciences?

IDEAYA Biosciences's mailing address is 7000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +65 04436209.
What is IDEAYA Biosciences stock forecast & price target?

Based on 8 Wall Street analysts` predicted price targets for IDEAYA Biosciences in the last 12 months, the avarage price target is $54.11. The average price target represents a 129.47% change from the last price of $23.58.

IDEAYA Biosciences, Inc.

ideayabio.com

Exchange:

NASDAQ

Full time employees:

124

Industry:

Biotechnology

Sector:

Healthcare

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

+65 04436209

7000 Shoreline Court
South San Francisco, CA 94080

CIK: 0001676725
ISIN: US45166A1025
CUSIP: 45166A102